1 paper and 0 clinical trials exploring esketamine as a treatment for interpersonal functioning & social connectedness.
Esketamine (Spravato) is the S-enantiomer of ketamine, approved as an intranasal treatment for treatment-resistant depression and MDD with acute suicidal ideation. It is administered under clinical supervision with post-dose monitoring and has reached over $1.6 billion in annual sales.
Full Esketamine profileResearch on psychedelics highlights their potential to enhance interpersonal functioning and social connectedness, particularly through compounds such as psilocybin and MDMA. These compounds may facilitate therapeutic outcomes in various mental health disorders by fostering emotional connectivity and empathy among individuals.
Full Interpersonal Functioning & Social Connectedness profileNo clinical trials have been tagged with both Esketamine and Interpersonal Functioning & Social Connectedness yet.
Trials are continuously being added as new studies are registered.